Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review.

Ghader Mohammadnezhad Behniya Azadmehr Mehdi Mirheidari Nazila Yousefi

Published in: Cost effectiveness and resource allocation : C/E (2022)

Results of cost-effectiveness analyses showed that adjunct dapagliflozin plus SCT is cost-effective compared to SCT alone despite the additional costs of the drug. Finally it can be concluded that dapagliflozin is a worldwide cost-effective as an adjunct medicine in HFrEF management.

Keyphrases

heart failure
cardiac resynchronization therapy
adverse drug